Hims & Hers: Potential Risks Ahead, But Shorting May Be Premature
Hims & Hers may leverage FDA compounding exemptions to further extend its compounded GLP-1 offerings. Learn why HIMS stock is ...
Health Canada issues recall notice for compounded semaglutide drugs
Health Canada has issued a recall notice for compounded drugs containing semaglutide, which is a key component in popular medications like Ozempic and Wegovy.
Business Insider on MSN6d
The FDA is about to make weight-loss drugs a lot harder to get
Lots of people are on cheaper compounded weight-loss drugs that mimic brands like Ozempic, Wegovy, and Zepbound. They're ...
News 6 WKMG5d
Weight loss drugs help users lose weight, change spending habits, studies show
Dr. George Carroll runs BeSlimMD, a private weight loss clinic in Maitland. He has been helping patients lose weight for more ...
JD Supra1d
The GLP-1 Saga Continues: FDA Ends the Tirzepatide Shortage: Frequently Asked Questions
FDA formally announced the end of the tirzepatide shortage in a Declaratory Order issued to Eli Lilly & Co. (“Lilly”). Lilly ...
pharmaphorum2d
Novo joins Lilly in asking FDA for ban on GLP-1 compounding
Novo Nordisk has asked the FDA to stop compounding pharmacies making cheaper versions of its semaglutide-based therapies for obesity and diabetes, saying the drug is too complex to be made safely ...
pharmaphorum1d
Noom offers cut-price compounded GLP-1 drug for obesity
Digital health company Noom has launched a compound pharmacy-made version of Novo Nordisk's obesity drug semaglutide to make the drug more accessible to consumers in the US. The bold move has been ...